Tessellate BIO
Lara Boyd currently serves as Chief Business Officer at Tessellate BIO since November 2024. Prior to this role, Lara Boyd held various positions at F-star, an invoX company, from March 2018 to July 2024, including VP, Head of Business Development & Corporate Strategy, and several director-level roles in business development. Lara Boyd's earlier experience includes managing commercial partnerships at Cancer Research UK, and several business development management roles at Cancer Research Technology. Lara Boyd began a research career as a Post-doctoral Research Scientist at Barts Cancer Institute and held academic positions at the University of Sussex, including Associate Tutor. Educational qualifications include a BSc (Hons) in Biochemistry from Imperial College London and both an MSc in Genetic Manipulation and Molecular Cell Biology and a PhD in DNA Damage Repair from the University of Sussex.
This person is not in any teams
This person is not in any offices
Tessellate BIO
Tessellate BIO discovers and develops novel precision oncology medicines with the mission to turn cancer patients into cancer survivors. A private preclinical stage biotechnology company, Tessellate BIO is redefining Synthetic Lethality by developing drugs that target unexplored or difficult to drug pathways beyond HRD. Headquartered in the Netherlands and with research labs at the Stevenage Bioscience Catalyst, UK, Tessellate BIO is supported by top-tier life science investors BioGeneration Ventures (BGV) and Forbion.